Q-omics provides the consensus-scored BMX profile across patient tissues and cancer cell-line models. BMX expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, BMX is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, BMX RNA expression shows 15,317 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, COAD, and TGCT as cancer lineages where BMX shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BMX — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BMX survival associations across molecular data types. BMX RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BMX RNA expression–survival associations across cancer types. High BMX expression shows favorable associations in KIRC, LIHC, UCEC, ACC, UCS and THCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for BMX RNA expression.
This table summarizes BMX tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for BMX. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BMX shows lower tumor expression in COAD, BLCA, LUAD, LUSC and HNSC and higher tumor expression in KIRC. The COAD box plot shows higher BMX RNA expression in normal versus tumor tissue (log2 FC = −2.417, t-test p < 0.001).
This table shows molecular features associated with BMX in patient tissues and cancer cell lines. In patient samples, BMX shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, BMX RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
